Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Ishares Msci Thailand Etf — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Ishares Msci Thailand Etf trades at $71.15 (market cap $424.09M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 6.7× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Ishares Msci Thailand Etf for 67 Days on average.
| DYN | THD | |
|---|---|---|
Market Cap | $2.86B | $424.09M |
Volume | 3,341,579 | 1,217,048 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $75.06 |
52-Week Low | $14.60 | $57.86 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
THD (iShares MSCI Thailand ETF) trades at $71.17, down 0.27% with bearish technical signals across moving averages and oscillators. Short interest surged 90.6% in September 2026 (Defense World, 2026-10-01), indicating rising bearish sentiment. The ETF has delivered strong 38% returns over the past year (Seeking Alpha, 2026-07-09) but faces headwinds from capital rotation away from Asian AI-related markets.
Outlook remains cautious given technical weakness and elevated short positioning. Investment opportunity exists for exposure to Thailand's AI hardware plays like Delta Electronics, but vulnerability to profit-taking and regional capital outflows presents significant near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
